
Vir Biotechnology Announces Results of its Potential Hepatitis B Cure Combination Therapy
Vir Biotechnology, a clinical-stage immunology company, announced results from its MARCH phase 2 trial, which showed the proportion of participants with undetectable hepatitis B surface antigen (HBsAg) at 24 weeks post-end of treatment, was achieved by 17% …